Gene · 3055
HCK: HCK proto-oncogene, Src family tyrosine kinase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HCK: HCK proto-oncogene, Src family tyrosine kinase. Genes, record 3055. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3055
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P08631 | Tyrosine-protein kinase HCK | 526 | 40 | Ensembl, GeneID, HGNC |
Source UniProt
Patents15
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025247951 A1 | 2025-12-04 | 61 | P08631 | Espacenet |
| US 11685954 B2 | 2023-06-27 | 255 | P08631 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1088 | P08631 | Espacenet |
| US 10190166 B2 | 2019-01-29 | 27 | P08631 | Espacenet |
| JP 2016104716 A | 2016-06-09 | 6 | P08631 | Espacenet |
| US 8986687 B2 | 2015-03-24 | 6 | P08631 | Espacenet |
| EP 2831104 A1 | 2015-02-04 | 1166 | P08631 | Espacenet |
| JP 2014526678 A | 2014-10-06 | 27 | P08631 | Espacenet |
| JP 2013510831 A | 2013-03-28 | 6 | P08631 | Espacenet |
| WO 2013034569 A1 | 2013-03-14 | 27 | P08631 | Espacenet |
1 to 10 of 15
See all 15 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BOSUTINIB | CHEMBL288441 | Tyrosine-protein kinase HCK inhibitor | INHIBITOR | ChEMBL |
| DASATINIB ANHYDROUS | CHEMBL1421 | SRC inhibitor | INHIBITOR | ChEMBL |
| ENMD-981693 | CHEMBL52885 | SRC inhibitor | INHIBITOR | ChEMBL |
| ILORASERTIB | CHEMBL1980297 | SRC inhibitor | INHIBITOR | ChEMBL |
| TG100-801 | CHEMBL403989 | SRC inhibitor | INHIBITOR | ChEMBL |
| XL-228 | CHEMBL3545085 | SRC inhibitor | INHIBITOR | ChEMBL |
Trials266
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06423911 | BOSUTINIB | PHASE3 | ClinicalTrials.gov | |
| NCT06390319 | DASATINIB ANHYDROUS | PHASE2 | ClinicalTrials.gov | |
| NCT06355037 | DASATINIB ANHYDROUS | PHASE2 | ClinicalTrials.gov | |
| NCT06336395 | DASATINIB ANHYDROUS | PHASE2 | ClinicalTrials.gov | |
| NCT06297161 | BOSUTINIB | ClinicalTrials.gov | ||
| NCT06124157 | DASATINIB ANHYDROUS | PHASE2 | ClinicalTrials.gov | |
| NCT06055621 | DASATINIB ANHYDROUS | PHASE2 | ClinicalTrials.gov | |
| NCT05993949 | DASATINIB ANHYDROUS | PHASE1 | ClinicalTrials.gov | |
| NCT05751044 | DASATINIB ANHYDROUS | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05559008 | DASATINIB ANHYDROUS | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 266
See all 266 trialsNIH grants1,893
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HCK papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 20 | 2025 |
| R01GM086858 | New Molecular Probes For Protein Kinases | 13 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 9 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 6 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 6 | 2025 |
| P01AI091580 | Defining the Unique Properties of the Distinct Signaling Machinery Used by the TCR | 5 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 5 | 2025 |
| R35GM119437 | Dynamics of Ligand Binding and Protein Kinase Regulation | 5 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
1 to 10 of 1,893Source NIH's project files
See all 1,893 nih grantsPapers2,931
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Elucidation of key lactylation- and palmitoylation-related genes and their related mechanisms in the development of neuropathic pain. | Medicine (Baltimore) | 2026 | 42826297 | PubTator, text mining | PubMed |
| Refining prostate cancer diagnosis: correlative analysis of Gleason scores and immunohistochemical markers. | Diagn Pathol | 2026 | 42823706 | PubTator, text mining | PubMed |
| Discovery of JH-XIII-05-01, a First-in-Class Dual IRAK1/IRAK4 Degrader for MYD88 Mutant Lymphomas. | ACS Med Chem Lett | 2026 | 42741641 | PubTator, text mining | PubMed |
| Identification of Critical Genes for Recurrent Aphthous Ulcer by Transcriptome Data Analysis and Mendelian Randomization. | Oral Health Prev Dent | 2026 | 42714320 | PubTator, text mining | PubMed |
| RAS P21 Protein Activator 3 finetunes Type I immunity by limiting HCK-mediated STAT4 phosphorylation. | Nat Commun | 2026 | 42686775 | PubTator, text mining | PubMed |
| In Silico and Molecular Docking Analysis of Benzyl Isothiocyanate from Salvadora persica as a Predicted Multi-Target Candidate for COVID-19 Host Responses. | Curr Issues Mol Biol | 2026 | 42651847 | PubTator, text mining | PubMed |
| Non-canonical function of transferrin receptor-1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling. | Clin Transl Med | 2026 | 42437977 | PubTator, text mining | PubMed |
| Machine learning-based integration develops a novel lysosome-related prognostic signature associated with prognosis and immune infiltration landscape in acute myeloid leukemia. | Discov Oncol | 2026 | 42334654 | PubTator, text mining | PubMed |
| Constraining regulatory domain dynamics of the Src kinase Fgr increases ATP-site inhibitor sensitivity and impairs bone marrow engraftment. | Cell Rep | 2026 | 42301812 | PubTator, text mining | PubMed |
| Synthetic Substrate Discovery for Hck Kinase via Phage Display. | Biochemistry | 2026 | 42283445 | PubTator, text mining | PubMed |
1 to 10 of 2,931
See all 2,931 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3055
GET https://conductscience.org/api/genes/v1/3055/patents